We are developing a prophylactic HIV-1 vaccine that aims to protect against all clades of HIV-1 through heterologous prime/boost regimens using adenovirus serotype 26 (Ad26) vectors expressing unique mosaic Gag, Pol, and Env antigens with soluble trimeric Env gp140 proteins to enhance humoral immunity. In December 2014, the program entered into its Phase 1/2a clinical phase assessing the safety and immunogenicity of Clade C gp140, trivalent Ad26.Mos.HIV vectors, and MVA.Mos.HIV vectors. Additional Phase 1/2a clinical studies started in 2016 and early 2017 are testing a tetravalent Ad26.Mos4.HIV and the addition of a Mosaic gp140 protein to the Clade C gp140 component. In an effort to explore simplification of the vaccine components, we propose to conduct additional ancillary clinical studies. Priority will be given to combinations evaluated in Project 1, including simplified vaccine composition. To secure availability of clinical trial materials, we propose GMP manufacturing activities that cover fill and finish, release assays, and characterization and stability testing of drug products. Finally, in order to support late stage development and characterization of selected vaccine candidates, we propose to perform bridging preclinical studies. In this Project, we hypothesize that our lead Ad26/Env vaccine will protect humans against multiple strains of HIV-1. Moreover, we hypothesize that simplified and shortened regimens will prove comparably immunogenic. To test these hypotheses we propose the following Specific Aims:
Specific Aim 1. To progress with the clinical evaluation of the lead candidate vaccines from Phase 1/2a to Phase 2b and Phase 3 clinical trials while in parallel exploring shorter and/or simplified regimens Specific Aim 2. To manufacture, release and characterize clinical vaccine products and to support CMC development with preclinical bridging studies

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI128751-03
Application #
9853728
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Barouch, Dan H; Tomaka, Frank L; Wegmann, Frank et al. (2018) Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392:232-243
Badamchi-Zadeh, Alexander; Moynihan, Kelly D; Larocca, Rafael A et al. (2018) Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. J Immunol 201:2744-2752
Alter, Galit; Barouch, Dan (2018) Immune Correlate-Guided HIV Vaccine Design. Cell Host Microbe 24:25-33
Bricault, Christine A; Kovacs, James M; Badamchi-Zadeh, Alexander et al. (2018) Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol :
Whitney, James B; Lim, So-Yon; Osuna, Christa E et al. (2018) Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat Commun 9:5429
Borducchi, Erica N; Liu, Jinyan; Nkolola, Joseph P et al. (2018) Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563:360-364
Barouch, Dan H (2018) A step forward for HIV vaccines. Lancet HIV 5:e338-e339